# Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.

> **NCT05609630** · PHASE3 · RECRUITING · sponsor: **AbbVie** · enrollment: 90 (estimated)

## Conditions studied

- Juvenile Idiopathic Arthritis

## Interventions

- **DRUG:** Upadacitinib
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT05609630
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-02
- **Primary completion:** 2029-06
- **Final completion:** 2029-06
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05609630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05609630, "Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT05609630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*